



## Microwave assisted synthesis, characterization & biological evaluation of 2-(phenoxyethyl)-1-[5-(substituted aryl)-1,3,4-oxadiazole-2-yl]-1H-benzimidazoles

Keshari Kishore Jha<sup>1\*</sup>, Y. Kumar<sup>2</sup>, Mohd Shaharyar<sup>3</sup>, Sachin Singhal<sup>4</sup>

<sup>1</sup>Teerthanker Mahaveer University, Muradabad, U.P. India

<sup>2</sup>Institute of Pharmaceutical Technology, ITS, Muradnagar, Ghaziabad, UP, India

<sup>3</sup>Faculty of Pharmaceutics, Jamia Hamdard, New Delhi, India

<sup>4</sup>NKBR College of Pharmacy & Research centre, Phaphunda, Meerut, UP, India.

Received on:17-10-2012; Revised on: 19-11-2012; Accepted on:10-01-2013

### ABSTRACT

In an effort to develop novel 1,3,4-oxadiazoles, with various substituents characterizing and biologically screening them for anticonvulsant and antibacterial activities, a series of benzimidazole containing 1,3,4-oxadiazoles were synthesized by microwave assisted methods from presynthesized acetohydrazide by refluxing them with substituted aromatic acids at appropriate temperature in the suitably designed experimental conditions. The synthesized compounds were characterized by means of their IR, HNMR data, Mass spectrophotometry and elemental analysis. All compounds were tested for their anticonvulsant (using MES method) and antibacterial (against *E. coli*, *S. aureus* etc) activities.

**Key words:** - Microwave, Benzimidazole, Oxadiazole, Anticonvulsant, Antimicrobial activity.

### INTRODUCTION

Benzimidazole & oxadiazole both are heterocyclic compounds which have been reported to possess anticonvulsant<sup>1-5</sup> and antimicrobial activities. Since long (400 BC) medicinal chemists are in search of single drug for the treatment of epilepsy in all of its seizure types. With such prime assumptions, the research work was aimed to incorporate both the heterocyclic systems in the single molecule for some better outcomes from these combinations. The earlier combinations have shown various biological activities such as antimicrobial<sup>6</sup>, anti-fungal<sup>7</sup>, antitubercular<sup>8</sup> etc.

In the present communication we report the synthesis of various benzimidazole containing 1,3,4-oxadiazoles (IVa-r) by the reaction of 2-[2-(phenoxyethyl)-3H-inole-3yl] acetohydrazide with differently substituted aromatic acids.

### EXPERIMENTAL

#### General

Melting points were determined in open glass capillary melting point apparatus and are uncorrected. The <sup>1</sup>HNMR was recorded in DMSO-

d<sub>6</sub> using TMS as internal standard. The IR spectrum was recorded on Shimadzu 8400S model FTIR spectrophotometer using KBr pellets. The elemental analysis was performed on Carlo Erba 1108 elemental analyzer. The molecular masses were confirmed by EI-MS studies. The purity of the compounds were checked by TLC using Silica Gel-G (Merk) with two solvent systems Benzene: Acetone (9:1) and (8:2) & Toluene: ethyl acetate: formic acid (5:4:1). Ash less Whatmann no. 1 filter paper was used for vacuum filtration. Column chromatography was performed on Silica Gel (Merk, 60-120 mesh).

General procedure for the preparation of benzimidazole containing 1,3,4-oxadiazoles (Iva-r) as represented in scheme – I.

#### Preparation of benzimidazole containing 1,3,4-oxadiazoles

**(a) Synthesis of 2-(phenoxyethyl)-1H-benzimidazol (I):**- A mixture of o-phenylene diamine (0.05 ml, 5.40gm) and phenoxyacetic acid (0.05 mole, 7.60g) was refluxed in 4NHCl for 30 min. in a microwave at 80° C. After completion of the reaction, solution was poured in to the crushed ice. Ammonia solution was added drop wise to neutralize the reaction mixture and the resulting solid was filtered, washed with cold water, dried and recrystallized in ethanol. TLC examination in TEF (5:4:1) the compound gave single spot.

**(b) Synthesis of ethyl[2-(phenoxyethyl)-1H-benzimidazol-1-yl]-acetate (II):**- To a suspension of compound-(I) (0.01 mole, 2.24g) & anhydrous K<sub>2</sub>CO<sub>3</sub> (2g) in dry acetone, ethyl chloroacetate (0.01 mole,


\*Corresponding author.

Prof. K.K. Jha,

410A,

Phase-3, Tridev Park,

Meerut-250004, India



Scheme - 1

1.2 ml) was added drop wise for 20-30 minutes at room temperature. The reaction mixture was stirred for 6 hrs with the help of magnetic stirrer at the temperature not exceeding 30-35<sup>o</sup> C. The inorganic solid thus obtained was filtered off and the filtrate was concentrated under reduced pressure, to produce a solid product (compound-II).

**(c) Synthesis of 2-[2-(phenoxyethyl)-3H-indol-3-yl]acetohydrazide (III):-** An ethanolic solution of compound II (0.01mole, 3.10g) was added with hydrazine hydrate (0.01 mole, 0.49 ml) and the mixture was refluxed in a round bottom flask in the microwave apparatus for 15 minutes at 30-40<sup>o</sup>C. After completion of the reaction, the mixture was

cooled and the solid thus obtained was filtered, washed with cold water and re crystallized from methanol.

**(d) Synthesis of 2-(phenoxyethyl)-1-[(5-aryl-1,3,4-oxadiazol-2-yl)methyl]-1H-benzimidazole (IVa):-** A mixture of presynthesized compound (III) (0.0025 mole, 0.738g) and benzoic acid (0.0025mole, 0.305g) was refluxed in the presence of POCl<sub>3</sub> (5ml) for 45 minutes in a microwave at a temperature of 80-85<sup>o</sup> C.

**(e) Synthesis of 2-(phenoxyethyl)-1-[(5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl)methyl]-1H-benzimidazole (IVb):-** The mixture of compound III (0.0025mole, 0.738g) and 2-methyl benzoic acid (0.0025mole, 0.340g) was refluxed in the presence of POCl<sub>3</sub> (5ml) for 30 minutes at 85<sup>o</sup>C in a microwave apparatus till the reaction completed.

**(f) Synthesis of 2-(phenoxyethyl)-1-[(5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl)methyl]-1H-benzimidazole (IVc):-** A mixture of 3-methylbenzoic acid (0.0025mole, 0.340g) and compound (III) (0.0025 mole, 0.738g) was added with POCl<sub>3</sub> (5ml) and refluxed for 35 minutes at a temperature of 85<sup>o</sup>C in a microwave apparatus till the reaction completed.


**(g) Synthesis of 2-(phenoxyethyl)-1-[(5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl)methyl]-1H-benzimidazole (IVd):-** The equimolar quantity (0.0025moles) of compound III (0.738g) and 4-methyl benzoic acid (0.34g) was refluxed with POCl<sub>3</sub> (5 ml) for 30 minutes in a microwave apparatus at the temperature of 80-85<sup>o</sup>C and completion of the reaction was judged.

**(h) Synthesis of 1-[(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-(phenoxyethyl)-1H-benzimidazole (IVe):-** An equimolar quantity (0.0025moles) of compound III (0.738g) and 1-chlorobenzoic acid (0.391g) were mixed with POCl<sub>3</sub> (5 ml), refluxed for 30 minutes in a microwave oven at the temperature of 90<sup>o</sup>C and completion of the reaction was judged.

**(i) Synthesis of 1-[(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-(phenoxyethyl)-1H-benzimidazole (IVf):-** Compound (IVf) was synthesized by the method as described for compound (IVe) except the reagents in this case were compound (III) (0.738g) and 4-chlorobenzoic acid (0.0391g) in equimolar quantities (0.0025 moles each) and reflux duration was 30 minutes at 85-90<sup>o</sup> C till the reaction completed.

**(j) Synthesis of 1-[(5-(2-bromophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-(phenoxyethyl)-1H-benzimidazole (IVg):-** The equimolar quantity (0.0025moles) of compound III (0.738g) and 2-bromobenzoic acid (0.502g) were refluxed in 5 ml POCl<sub>3</sub> at 80-85<sup>o</sup>C for 40 minutes until the reaction completed.

**(k) Synthesis of 1-[(5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl)methyl]-2-(phenoxyethyl)-1H-benzimidazole (IVh):-** 0.0025 moles each of compound(III) (0.738g) 4- bromobenzoic acid (0.502g) were mixed,



S.No.	Compounds Name	Structure of Ar
1.	IV a	<p>Phenyl</p>
2.	IV b	<p>2- methylphenyl</p>
3.	IV c	<p>3- methylphenyl</p>
4.	IV d	<p>4- methylphenyl</p>
5.	IV e	<p>2- chlorophenyl</p>
6.	IV f	<p>4- chlorophenyl</p>
7.	IV g	<p>2- bromophenyl</p>
8.	IV h	<p>4 - bromophenyl</p>
9.	IV i	<p>2- nitrophenyl</p>

S.No.	Compounds Name	Structure of Ar
10.	IV j	<p>4- nitrophenyl</p>
11.	IV k	<p>4- methoxyphenyl</p>
12.	IV l	<p>3,4- dimethoxyphenyl</p>
13.	IV m	<p>benzyl</p>
14.	IV n	<p>phoxymethyl</p>
15.	IV o	<p>naphthylmethyl</p>
16.	IV p	<p>biphenylmethyl</p>
17.	IV q	<p>2- aminophenyl</p>
18.	IV r	<p>4- pyridinyl</p>

added with 5ml POCl<sub>3</sub> and refluxed in a microwave oven at 75-80<sup>o</sup> C for 45 minutes until the reaction was complete.

**(l) Synthesis of 1-[[5-(2-nitrophenyl)-1,3,4-oxadiazol-2yl]methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV i):-** 2-nitrobenzoic acid (0.417g) was added with compound III (0.738g) in equimolar quantities (0.0025 moles) and the mixture was refluxed with 5 ml POCl<sub>3</sub> at the temperature of 90-95<sup>o</sup> C in a microwave apparatus till the reaction was complete.

**(m) Synthesis of 1-[[5-(4-nitrophenyl)-1,3,4-oxadiazol-2yl]methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV j):-** The equimolar quantities (0.0025 mole) of compound III (0.738g) and 4-nitrobenzoic acid (0.417g) were mixed in dried powder form and added with 5 ml of POCl<sub>3</sub>. The mixture was refluxed in a microwave apparatus at the temperature of 85-90<sup>o</sup> C for 30 minutes until the reaction was complete.

**(n) Synthesis of 2-(phenoxy methyl)-1-[[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2yl]methyl]-1H-benzimidazole (IV k):-** 4-methoxybenzoic acid (0.380g) and compound III (0.738g) were mixed together in equimolar quantities (0.0025 moles) and mixture was added with 5 ml POCl<sub>3</sub>. The produced reaction mixture was refluxed in a microwave oven at the temperature of 90-92<sup>o</sup> C for 40 minutes until the reaction was complete.

**(o) Synthesis of 2-(phenoxy methyl)-1-[[5-(3,4-dimethoxyphenyl)-1,3,4-oxadiazol-2yl]methyl]-1H-benzimidazole (IV l):-** In 5 ml of POCl<sub>3</sub>, equimolar amounts (0.0025 moles) each of compound III (0.738g) and 3,4-dimethoxybenzoic acid (0.455g) were mixed together and refluxed in a microwave apparatus at the temperature of 80-85<sup>o</sup> C for 25-30 minutes.

**(q) Synthesis of 1-[[5-(5-benzyl-1,3,4-oxadiazol-2yl)methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV m):-** An equimolar amounts (0.0025 moles) of compound III (0.738g) and phenylacetic acid (0.340g) was refluxed in 5 ml POCl<sub>3</sub> at the temperature of 95-100<sup>o</sup> C for 25-30 minutes in a microwave apparatus.

**(r) Synthesis of 1-[[5-(5-phenoxy methyl-1,3,4-oxadiazol-2yl)methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV n):-** A mixture containing equimolar quantities (0.0025 moles) of compound III (0.738g) and phenoxyacetic acid (0.380g) was refluxed with 5 ml POCl<sub>3</sub> in a microwave apparatus at the temperature of 90-95<sup>o</sup> C for 25-30 minutes. The completion of reaction was judged markably.

**(s) Synthesis of 1-[[5-(5-naphthylmethyl-1,3,4-oxadiazol-2yl)methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV o):-** A mixture of compound III n(0.0025 mole, 0.738g) and  $\alpha$ - naphthylacetic acid (0.0025mole, 0.315g) was refluxed in the presence of POCl<sub>3</sub> (5 ml) in a microwave oven at the temperature of 85-90<sup>o</sup> C for 30-35 minutes till the completion of reaction .

**(t) Synthesis of 1-[[5-(5-diphenyl -1,3,4-oxadiazol-2yl)methyl]-2-(phenoxy methyl)-1H-benzimidazole (IV p):-** A mixture of compound

III (0.0025 mole, 0.738g) and biphenylacetic acid (0.0025 mole, 0.538g) was refluxed with POCl<sub>3</sub> (5ml) in a microwave apparatus at the temperature of 80-85<sup>o</sup> C for 45 minutes until the reaction completed.

**(t) Synthesis of 2-[5{2- phenoxy methyl)-1H-benzimidazol-1-yl]methyl]-1,3,4-oxadiazole-2yl]aniline (IV q):-** Compound III(0.738g) and anthranilic acid (0.342g) in equimolar quantities (0.0025 moles) were mixed in dried powder form and added with 5 ml POCl<sub>3</sub> (dried). The reaction mixture was refluxed at the temperature of 88-92<sup>o</sup> C for 35-37 minutes in a microwave apparatus until the reaction completed.

**(u) Synthesis of 2-[(phenoxy methyl )-1-[(5-pyridine-4yl-1,3,4-oxadiazole-2yl)methyl]-1H-benzimidazole (IV r):-** The equimolar quantities (0.0025 mole) of compound III (0.738g) and nicotinic acid (0.307g) were refluxed 5ml POCl<sub>3</sub> at the temperature of 90<sup>o</sup>-95<sup>o</sup> C for 35-40 minutes in a microwave apparatus until the reaction completed. After completion of the reaction, the mixture was cooled at the room temperature, poured in crushed ice, and it was basified with 5 % (w/v) solution of sodium bicarbonate. The solid mass obtained in each case was separated out, washed with water and recrystallized from alcohols or suitable solvents.

Compound IVa, IVc, IVd, IVf, IVg, IVh, IVi, IVj, IVk, IVl, IVn, IVo, IVp were recrystallized from methanol and rest others from ethanol except IVr from petroleum ether.

#### **Spectral Analysis:**

Almost eighteen new 2-benzimidazole substituted 1,3,4- Oxadiazoles were synthesized. IR, <sup>1</sup>HNMR & Mass spectra were recorded and all of them found in agreement with structural consignments.

**Compound IVa (Ar = Phenyl):** Yield: 78%; m.pt: 148<sup>o</sup>-152<sup>o</sup> C. IR(KBR, Cm<sup>-1</sup>): 1034(N-N); 1241(C-O); 1602(C=N). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>,  $\delta$  ppm): 5.52(s, 2H, CH<sub>2</sub>); 6.04(s, 2H, OCH<sub>2</sub>); 7.00(s, 3H, H 5, 7, 9); 7.25(s, 4H, H 6, 8, 11, 13); 7.56(s, 3H, H 2, 3, 4); 7.73-7.81(d, 4H, 1, 10, 12, 14). m/z (M<sup>+</sup>382). Anal calcd for C<sub>23</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub>: C, 72.25; H, 4.71; N, 14.65; O, 8.38. Found: C, 73.82; H, 4.96; N, 14.38; O, 8.40.

**Compound IVb (Ar = 2-methyl phenyl):** Yield: 60%; m.pt: 138<sup>o</sup>-140<sup>o</sup> C. IR(KBR, Cm<sup>-1</sup>): 1034(N-N); 1239(C-O); 1593(C=N); 3056(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>,  $\delta$  ppm): 2.48(s, 3H, CH<sub>3</sub>); 5.45(s, 2H, CH<sub>2</sub>); 5.93(s, 2H, OCH<sub>2</sub>); 6.83 – 6.87(m, 2H, H 7, 11); 6.92 – 6.94(d, 2H, H 5, 9); 7.14-7.36(m, 6H, H 2, 3, 6, 8, 10, 12); 7.57-7.59(m, 3H, H 1, 4, 13). m/z (M<sup>+</sup>396). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 72.72; H, 5.05; N, 14.14; O, 8.08. Found: C, 72.14; H, 5.25; N, 14.30; O, 8.10.

**Compound IVc (Ar = 3-methyl phenyl):** Yield: 60%; m.pt: 170<sup>o</sup>-172<sup>o</sup> C. IR(KBR, Cm<sup>-1</sup>): 1031(N-N); 1238(C-O); 1600(C=N); 3032(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>,  $\delta$  ppm): 3.21-3.38(d, 3H, CH<sub>3</sub> merged with H<sub>2</sub>O in DMSO); 5.50(s, 2H, CH<sub>2</sub>); 6.03(s, 2H, OCH<sub>2</sub>); 6.99(s, 3H, H 5, 7, 9); 7.23(s, 4H, H 2, 3, 12, 13); 7.43(s, 2H, H 6, 8); 7.64(s, 2H, H 10, 11); 7.72(s, 2H, H 1, 4). m/z (M<sup>+</sup>395). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 72.72; H, 5.05; N, 14.14; O, 8.08. Found: C, 71.96; H, 5.24; N, 14.60; O, 8.16.

**Compound IVd (Ar = 4-methyl phenyl):** Yield: 66%; m.pt: 164<sup>o</sup>-166<sup>o</sup> C. IR(KBR, Cm<sup>-1</sup>): 1237(N-N); 1277(C-O); 1654(C=N). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>,  $\delta$  ppm): 2.37(s, 3H, CH<sub>3</sub>); 5.50(s, 2H, CH<sub>2</sub>); 6.02(s, 2H, OCH<sub>2</sub>); 6.91–7.00(m, 3H, H 5, 7, 9); 7.22-7.37(m, 6H, 1, 2, 3, 4, 6, 8); 7.69-7.71(d, 4H, H



10, 11, 12, 13). m/z (M<sup>+</sup>397). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 72.72; H, 5.05; N, 14.14; O, 8.08. Found: C, 72.80; H, 5.20; N, 14.56; O, 8.38.

**Compound IVe (Ar = 2-chlorophenyl):** Yield: 72%; m.pt: 170°- 173°C. IR(KBR, Cm<sup>-1</sup>): 737(C-Cl); 1239(C-O); 1600(C=N); 2982(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.50(s, 2H, CH<sub>2</sub>); 6.07(s, 2H, OCH<sub>2</sub>); 6.91-6.96(t, 3H, H 5, 7, 9); 7.15-7.34(m, 5H, H 6, 8, 11, 12, 13); 7.59-7.65(t, 2H, H 2, 3); 7.70-7.78(m, 3H, H 1, 4, 10). m/z (M<sup>+</sup>416). Anal calcd for C<sub>23</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 66.18; H, 4.07; N, 13.43; O, 7.67. Found: C, 66.24; H, 4.14; N, 13.62; O, 7.22.

**Compound IVf (Ar = 4-chlorophenyl):** Yield: 69%; m.pt: 236°- 238°C. IR(KBR, Cm<sup>-1</sup>): 740(C-Cl); 1092(N-N); 1238(C-O); 1608(C=N). 3155(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.47(s, 2H, CH<sub>2</sub>); 6.01(s, 2H, OCH<sub>2</sub>); 6.87-6.94(m, 3H, H 5, 7, 9); 7.18-7.32(m, 4H, H 2, 3, 6, 8); 7.60(d, 2H, H 10, 13); 7.70-7.71(d, 2H, H 11, 12); 7.76-7.78(d, 2H, H 1, 4). m/z (M<sup>+</sup>417). Anal calcd for C<sub>23</sub>H<sub>17</sub>ClN<sub>4</sub>O<sub>2</sub>: C, 66.18; H, 4.07; N, 13.43; O, 7.67. Found: C, 66.08; H, 3.97; N, 13.35; O, 7.46.

**Compound IVg (Ar = 2-bromophenyl):** Yield: 80%; m.pt: 160°- 162°C. IR(KBR, Cm<sup>-1</sup>): 738(C-Br); 1082(N-N); 1240(C-O); 1592(C=N); 3062(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.50(s, 2H, CH<sub>2</sub>); 6.08(s, 2H, OCH<sub>2</sub>); 6.88-6.97(m, 3H, H 7, 11, 12); 7.29-7.37(m, 4H, H 2, 3, 6, 8); 7.52-7.55(t, 2H, H 5, 9); 7.70-7.75(t, 3H, H 1, 4, 13); 7.81-7.83(d, 1H, 10). m/z (M<sup>+</sup>462). Anal calcd for C<sub>23</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>2</sub>: C, 59.87; H, 3.69; N, 12.15; O, 6.94. Found: C, 59.68; H, 3.56; N, 12.22; O, 6.68.

**Compound IVh (Ar = 4-bromophenyl):** Yield: 76%; m.pt: 204°- 206°C. IR(KBR, Cm<sup>-1</sup>): 738(C-Br); 1083(N-N); 1241(C-O); 1604(C=N). 2917(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.57(s, 2H, CH<sub>2</sub>); 5.85(s, 2H, OCH<sub>2</sub>); 6.99-7.03(t, 1H, H 7); 7.08-7.10(d, 2H, H 5, 9); 7.26-7.36(m, 4H, H 2, 3, 6, 8); 7.52-7.57(m, 5H, H 4, 10, 11, 12, 13); 7.80-7.82(m, 1H, H 1). m/z (M<sup>+</sup>460). Anal calcd for C<sub>23</sub>H<sub>17</sub>BrN<sub>4</sub>O<sub>2</sub>: C, 59.87; H, 3.69; N, 12.15; O, 6.94. Found: C, 59.36; H, 3.72; N, 12.32; O, 6.74.

**Compound IVi (Ar = 2-nitrophenyl):** Yield: 58.10%; m.pt: 226°- 228°C. IR(KBR, Cm<sup>-1</sup>): 1035(N-N); 1239(C-O); 1566 and 1350(NO<sub>2</sub>); 1685(C=N); 3063(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.38(s, 2H, CH<sub>2</sub>); 5.61(s, 2H, OCH<sub>2</sub>); 6.88-6.93(t, 1H, H 7); 7.04-7.06(d, 2H, H 5, 9); 7.23-7.27(t, 4H, H 2, 3, 11, 12); 7.58-7.61(d, 1H, H 7); 7.67-7.68(t, 2H, H 10, 13); 7.76-7.81(t, 1H, H 8); 8.01-8.09(t, 2H, H 1, 4). m/z (M<sup>+</sup>427). Anal calcd for C<sub>23</sub>H<sub>17</sub>N<sub>5</sub>O<sub>4</sub>: C, 64.64; H, 1.64; N, 16.39; O, 14.98. Found: C, 64.80; H, 1.52; N, 16.98; O, 14.96.

**Compound IVj (Ar = 4-nitrophenyl):** Yield: 70 %; m.pt: 232°- 234°C. IR (KBR Cm<sup>-1</sup>): 1036(N-N); 1237(C-O); 1287 and 1349(NO<sub>2</sub>); 1598(C=C); 1630(C=N). <sup>1</sup>HNMR (DMSO- d<sub>6</sub>, δ ppm): 5.50(s, 2H, CH<sub>2</sub>); 6.04(s, 2H, OCH<sub>2</sub>); 6.96-6.98(m, 3H, H 5, 7, 9); 7.26-7.40(m, 6H, H 2, 3, 6, 8, 11, 12); 7.71-7.76(m, 4H, H 1, 4, 10, 13). m/z (M<sup>+</sup>426). Anal calcd for C<sub>23</sub>H<sub>17</sub>N<sub>5</sub>O<sub>4</sub>: C, 64.64; H, 1.64; N, 16.39; O, 14.98. Found: C, 64.76; H, 1.49; N, 16.17; O, 14.68.

**Compound IV k (Ar = 4-methoxyphenyl):** Yield: 80%; m.pt: 168°- 170°C. IR(KBR, Cm<sup>-1</sup>): 1028 (N-N); 1256(C-O); 1610 (C=N); <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 3.82(s, 3H, OCH<sub>3</sub>); 5.51(s, 2H, CH<sub>2</sub>); 6.01(s, 2H, OCH<sub>2</sub>); 6.94-7.01(t, 3H, H 5, 7, 9); 7.07-7.10(d, 2H, H 6, 8); 7.25-7.35(m, 4H, H 2, 4, 11, 12); 7.73(s, 4H, H 1, 3, 10, 13). m/z (M<sup>+</sup>413). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>: C, 69.90; H, 4.85; N, 13.59; O, 11.65. Found: C, 69.38; H, 4.90; N, 13.20; O, 11.76.

**Compound IVl (Ar = 2-dimethoxy phenyl):** Yield: 85 %; m.pt: 182°- 184°C. IR(KBR, Cm<sup>-1</sup>): 1025(N-N); 1240(C-O); 1600(C=N); 3025(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 3.83(s, 6H, OCH<sub>3</sub>); 5.50(s, 2H, CH<sub>2</sub>); 6.00(s, 2H, OCH<sub>2</sub>); 6.92-6.99(m, 3H, H 5, 7, 9); 7.02(d, 1H, H 12); 7.23-7.36(m, 6H, H 2, 3, 6, 8, 10, 11); 7.70-7.75(s, 2H, H 1, 4). m/z (M<sup>+</sup>441). Anal calcd for C<sub>25</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>: C, 67.87; H, 4.98; N, 12.66; O, 14.48. Found: C, 67.93; H, 4.90; N, 12.39; O, 14.26.

**Compound IVm (Ar = 2-benzyl):** Yield: 75 %; m.pt: 234°- 236°C. IR(KBR, Cm<sup>-1</sup>): 1034(N-N); 1239(C-O); 1610(C=N); 3178(CH-Ar). <sup>1</sup>HNMR (DMSO-d<sub>6</sub>, δ ppm): 4.17(s, 2H, CH<sub>2</sub> benzylic); 4.96(s, 2H, CH<sub>2</sub>); 5.29(s, 2H, OCH<sub>2</sub>); 6.96-7.03(t, 1H, H 7); 7.09-7.12(d, 2H, H 5, 9); 7.24-7.28 (Broad peak, 9H, H 2, 3, 6, 8, 10, 11, 12, 13, 14); 7.51-7.54(d, 1H, H 4); 7.64-7.66(d, 1H, H 1). m/z (M<sup>+</sup>396). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 72.72; H, 5.05; N, 14.14; O, 8.08. Found: C, 72.98; H, 4.98; N, 13.89; O, 08.30.

**Compound IVn (Ar = 2-phenoxyethyl):** Yield: 73 %; m.pt: 224°- 226°C. IR (KBR, Cm<sup>-1</sup>): 1079(N-N); 1220(C-O); 1623(C=N); 3055(CH-Ar). <sup>1</sup>HNMR (DMSO-d<sub>6</sub>, δ ppm): 4.61(s, 2H, OCH<sub>2</sub> phenoxy); 5.12(s, 2H, CH<sub>2</sub>); 5.39(s, 2H, OCH<sub>2</sub>); 6.97(s, 4H, H 5, 7, 9, 12); 7.11-7.13(d, 2H, H 10, 14); 7.29(s, 6H, H 2, 3, 6, 8, 11, 13); 7.53-7.56(d, 1H, H 4); 7.65-7.67(d, 1H, H 1). m/z (M<sup>+</sup>411). Anal calcd for C<sub>24</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>: C, 69.90; H, 4.85; N, 13.59; O, 11.65. Found: C, 69.89; H, 4.68; N, 13.87; O, 11.46.

**Compound IVo (Ar = a-methylnaphthyl):** Yield: 65 %; m.pt: 138°- 140°C. IR(KBR, Cm<sup>-1</sup>): 1036(N-N); 1201(C-O); 1711(C=N); 3158(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 3.99(s, 2H, CH<sub>2</sub> Naphthyl); 5.24(s, 2H, CH<sub>2</sub>); 5.51(s, 2H, OCH<sub>2</sub>); 7.00(s, 1H, H 7); 7.11-7.14(d, 2H, H 5, 9); 7.30-7.51(m, 7H, H 2, 4, 6, 8, 11, 12, 15); 7.73-7.78(m, 4H, H 1, 3, 13, 16); 7.92-8.10(s, 2H, H 10, 14). m/z (M<sup>+</sup>445). Anal calcd for C<sub>28</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C, 75.33; H, 4.93; N, 12.56; O, 7.17. Found: C, 75.03; H, 4.86; N, 12.74; O, 7.34.

**Compound IVp (Ar = 2-biphenylmethyl):** Yield: 62%; m.pt: 152°- 154°C. IR(KBR, Cm<sup>-1</sup>): 1036(N-N); 1240(C-O); 1613(C=N); 3142(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.16(s, 2H, CH<sub>2</sub> biphenyl); 5.42(s, 2H, CH<sub>2</sub>); 5.96(s, 2H, OCH<sub>2</sub>); 6.82-6.85 (d, 2H, H 7, 10); 6.91-6.95(t, 2H, H 5, 9); 7.18-7.27(broad multiplet, 14H, H 2, 3, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18); 7.63-7.71(m, 2H, H 1, 4). m/z (M<sup>+</sup>471). Anal calcd for C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: C, 76.27; H, 5.08; N, 1.18; O, 6.78. Found: C, 76.46; H, 5.40; N, 1.26; O, 6.46.

**Compound IVq (Ar = 2-aminophenyl):** Yield: 56%; m.pt: 170°- 172°C. IR(KBR, Cm<sup>-1</sup>): 1036(N-N); 1238(C-O); 1626(C=N); 3392(N-H). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.51(s, 2H, CH<sub>2</sub>); 6.02(s, 2H, OCH<sub>2</sub>); 6.55-6.60(t, 2H, H 5, 7); 6.66(s, 1H, H 11); 6.84-7.01(m, 4H, H 2, 3, 5, 9); 7.23-7.33(m, 5H, H 1, 4, 6, 8, 12); 7.70-7.72(d, 2H, H 10, 13). m/z (M<sup>+</sup>398). Anal calcd for C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>: C, 69.52; H, 4.78; N, 4.79; O, 8.06. Found: C, 69.70; H, 4.64; N, 4.37; O, 8.28.

**Compound IVr (Ar = 2-pyridinyl):** Yield: 60%; m.pt: 210°- 212°C. IR(KBR, Cm<sup>-1</sup>): 1083(N-N); 1237(C-O); 1731(C=N); 3107(CH-Ar). <sup>1</sup>HNMR(DMSO-d<sub>6</sub>, δ ppm): 5.25(s, 2H, CH<sub>2</sub>); 5.47(s, 2H, OCH<sub>2</sub>); 6.97-7.02(t, 1H, H 7); 7.07-7.35(d, 2H, H 5, 9); 7.30-7.35(m, 4H, H 2, 3, 6, 8); 7.68-7.73(t, 2H, H 1, 4); missing peak(d<sub>each</sub>, 2x2H, H 10, 11, 12, 13). m/z (M<sup>+</sup>384). Anal calcd for C<sub>22</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>: C, 68.93; H, 4.44; N, 1.83; O, 8.35. Found: C, 68.72; H, 5.02; N, 1.38; O, 8.18.

#### Biological Evaluations :

The compounds were evaluated for anticonvulsant activity by deter-

mining their ability to provide protection against convulsions induced by electroconvulsimeter in albino mice using phenytoin (25 mg/kg body weight) as the reference drug. Antimicrobial screening of the synthesized compounds were performed for their activity against *S. aureus* and *E. Coli* by agar diffusion techniques using ofloxacin (50mg/ml) as the reference drug. All experiments were approved by the Animal Ethical Committee of the Institute.

**Anticonvulsant Activity :**

The investigations were conducted on albino mice of either sex (25-30g) which were kept under standard condition at an ambient temperature of 25 ± 2°C. Food and water were withdrawn prior to the experimentation. The compounds were screened for their anticonvulsant activity by Maximal Electro shock seizure (MES) method as reported by (Krall et al<sup>9</sup>) Supramaximal electroshock of current intensity of 50mA, 60 Hz for 0.2 sec duration was given to mice administered with the equimolar dose of standard (phenytoin : 25mg/kg body weight) and the test (31.77-46.72 mg/kg body wt). The abolition of the hind tonic extensor spasm was recorded as an increased anticonvulsant activity. The results have been shown in table :

**Antimicrobial Activity :**

The principle<sup>10</sup>, involved in the antimicrobial evaluation, is the inhibition of microbial growth under standard condition utilized for demonstrating the therapeutic efficacy of any subtle change in any antimicrobial molecule. The present work revealed the efficacy of eighteen compounds (IVa-r) determined against *S.aureus* (gram (+)ve) and *E. Coli* (gram (-) ve) microbes.

The nutrient agar medium was prepared and autoclaved at 15.1 lbs pressure for 20 mins. The medium was poured into Petri plate and allowed to solidify. On the surface of medium, the microbial suspension was spread with the help of sterilized cotton swab. Five cups were made in each Petri plate. Afterwards, the concentrations (50 mcg/ml, 100 mcg/ml and 200 mcg/ml) of test compounds were added into first three cups. The fourth was filled with standard and finally fifth one was filled with control (DMSO). The plates were kept in cold for one hour to allow the diffusion of test compds and then after incubated for 24 hrs. at a temperature of 37 + 0.5°C. The zone of inhibition was measured and % inhibition of each test compd was calculated.

**Table 2 : Anticonvulsant activity of compounds (IV<sub>a</sub>-IV<sub>r</sub>)**

S.No.	Compound No.	Ar	Anticonvulsant Activity MES (60 min) % Protection
1	IV <sub>a</sub>	C <sub>6</sub> H <sub>5</sub>	66.66*
2	IV <sub>b</sub>	2-CH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	66.66*
3	IV <sub>c</sub>	3-CH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	50.00
4	IV <sub>d</sub>	4-CH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	66.66*
5	IV <sub>e</sub>	2-ClC <sub>6</sub> H <sub>5</sub>	83.33**
6	IV <sub>f</sub>	4-ClC <sub>6</sub> H <sub>5</sub>	66.66*
7	IV <sub>g</sub>	2-BrC <sub>6</sub> H <sub>5</sub>	100***
8	IV <sub>h</sub>	4-BrC <sub>6</sub> H <sub>5</sub>	83.33**
9	IV <sub>i</sub>	2-NO <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	66.66*
10	IV <sub>j</sub>	4-NO <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	33.33
11	IV <sub>k</sub>	4-OCH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	66.66*
12	IV <sub>l</sub>	3,4-diOCH <sub>3</sub> C <sub>6</sub> H <sub>5</sub>	83.33**
13	IV <sub>m</sub>	C <sub>6</sub> H <sub>5</sub> CH <sub>2</sub>	66.66*
14	IV <sub>n</sub>	C <sub>6</sub> H <sub>5</sub> OCH <sub>2</sub>	66.66*
15	IV <sub>o</sub>	C <sub>10</sub> H <sub>7</sub> CH <sub>2</sub>	50.00
16	IV <sub>p</sub>	C <sub>12</sub> H <sub>9</sub> CH <sub>2</sub>	50.00
17	IV <sub>q</sub>	2-NH <sub>2</sub> C <sub>6</sub> H <sub>5</sub>	66.66*
18	IV <sub>r</sub>	C <sub>5</sub> H <sub>4</sub> N	66.66*
19	Phenytoin		100***

\*P<0.05, \*\*P,0.01, \*\*\*P,0.001

**Table 3 : Antibacterial activity of compounds (IV<sub>a</sub>-IV<sub>r</sub>) against *E. Coli***

The reference drug **Ofloxacin** showed the zone of inhibition (32 mm) at 50 µg/ml concentration.

Compd	Zone of Inhibition (mm)			% Inhibition		
	50 µg/ml	100 µg/ml	200 µg/ml	50 µg/ml	100 µg/ml	200 µg/ml
IV <sub>a</sub>	12	15	17	-	+	+
IV <sub>b</sub>	13	15	16	+	+	+
IV <sub>c</sub>	12	13	16	-	+	+
IV <sub>d</sub>	22	24	27	++	++	+++
IV <sub>e</sub>	13	14	17	+	+	+
IV <sub>f</sub>	23	25	29	++	++	+++
IV <sub>g</sub>	14	16	18	+	+	+
IV <sub>h</sub>	15	17	19	+	+	++
IV <sub>i</sub>	11	14	16	-	+	+
IV <sub>j</sub>	13	15	18	+	+	+
IV <sub>k</sub>	10	14	17	-	+	+
IV <sub>l</sub>	12	15	19	-	+	+
IV <sub>m</sub>	13	14	16	+	+	+
IV <sub>n</sub>	10	12	14	-	-	+
IV <sub>o</sub>	15	17	18	+	+	+
IV <sub>p</sub>	16	18	20	+	+	++
IV <sub>q</sub>	11	13	15	-	+	+
IV <sub>r</sub>	21	24	28	++	++	+++

% inhibition of ofloxacin -++++ (100%)

+++ (80%-99%), ++ (60%-79%), + (40%-59%), - (<39% or no activity)

**Table 4: Antibacterial activity of compounds (IV<sub>a</sub>-IV<sub>r</sub>) against *S. aureus***

The reference drug **Ofloxacin** showed the zone of inhibition (32 mm) at 50 µg/ml concentration.

Compd	Zone of Inhibition (mm)			% Inhibition		
	50 µg/ml	100 µg/ml	200 µg/ml	50 µg/ml	100 µg/ml	200 µg/ml
IV <sub>a</sub>	10	13	17	-	+	+
IV <sub>b</sub>	12	16	19	+	+	++
IV <sub>c</sub>	13	15	18	+	+	+
IV <sub>d</sub>	23	25	28	++	++	+++
IV <sub>e</sub>	14	17	20	+	+	++
IV <sub>f</sub>	21	25	27	++	++	+++
IV <sub>g</sub>	09	13	15	-	+	+
IV <sub>h</sub>	12	13	16	+	+	+
IV <sub>i</sub>	14	16	19	+	+	++
IV <sub>j</sub>	13	17	20	+	+	++
IV <sub>k</sub>	11	14	16	-	+	+
IV <sub>l</sub>	11	14	17	-	+	+
IV <sub>m</sub>	13	17	19	+	+	++
IV <sub>n</sub>	15	18	19	+	+	++
IV <sub>o</sub>	16	18	20	+	+	++
IV <sub>p</sub>	10	14	17	-	+	+
IV <sub>q</sub>	13	14	17	+	+	+
IV <sub>r</sub>	23	25	29	++	++	+++

% inhibition of ofloxacin -++++ (100%)

+++ (80%-99%), ++ (60%-79%), + (40%-59%), - (<39% or no activity)

**RESULT & DISSCUSSION:**

Anticonvulsant studies of these compounds revealed that compd IV<sub>g</sub> was equipotent with that of the standard (i.e. 100% protection) at equimolar dose. Compds IV<sub>e</sub>, IV<sub>h</sub> & IV<sub>l</sub> showed equal protection of 83.33% and rest other compds of the series exhibited anticonvulsant activity between 50.0% - 66.66% at equimolar dose to phenytoin.

The antimicrobial studies revealed that compds IV<sub>d</sub>, IV<sub>f</sub> & IV<sub>r</sub> showed more than 80% inhibition against *E. Coli* (NCTE 6571) at the concentration of 200 mcg/ml Rest other compds exhibited inhibition between 40% - 79% against *E. Coli*.

The screening against *S.aureus* (NCTE 7447) described that compds IV<sub>d</sub>, IV<sub>f</sub> & IV<sub>r</sub> produced 80% inhibition at the concentration of 200mcg/ml. Rest other compds elicited % inhibition ranging between 40% - 79% against *S.aureus*.

#### **ACKNOWLEDGEMENT:**

The authors are thankful to :

1. Head, Deptt. Of Pathology, L.L.R.M. Medical College, Meerut, U.P. India for providing the screened microbial culture of *E. Coli* (NCTE 6571) & *S. aureus* (NCTE 7447) for antimicrobial studies.
2. Head, Deptt. Of Pharmacology, L.L.R.M. Medical College, Meerut U.P. India for extending solehearted cooperation in anticonvulsant studies.
3. Chairman, Er. Vishnu Saran, MIET, Meerut, U.P. India for providing the entire research facilities in the Deptt. Of Pharmaceutical Technology, MIET, Meerut, UP, India
4. Head, 'Sophisticated Instrumentation Facility' NCL, Pune, Maharastra, India, for elemental analysis.
5. Prof. (Dr.) Paul. W Groundwater, Sunderland Pharmacy School, University of Sunderland SR, 3SD, U.K. for spectral measurements and wise interpretation.

#### **REFERENCES:**

1. Tripathi K D, *The Text Book of Medical Pharmacology 5<sup>th</sup> edition*. J P Publication New Delhi, 2003, 369
2. Browne T R and Holmes G L, *New Eng J Med*, 2001, 344, 1145
3. McNamara J O, Hardman J G, Limbard L E, Mollinoff P B, Ruddan R W and Gilman A G, *The Pharmacological Basis of Therapeutics*. McGraw Hill, New York, 9<sup>th</sup> edition, 1990, 461
4. Bin H, Prabha M V, Sharon F C, Christine N H, Peter H A, Albert M C, Ahmad A A, David S R and Jame P S, *Eur J Med Chem*, 33, 1998, 23
5. David A W, Thomas L L and Foye W O, *Principal of Medicinal Chemistry, 4<sup>th</sup> edition*. Lippincott Willian and Wilkins, Philadelphia, 2002, 384
6. Afaf H E, Fashmy H H and Abdulwal S H, *Molecules* 5, 2009, 1429
7. Sangwan N K and Dubey A K, *Ind. J Chem*, 33B, 1994, 1043
8. Kaghtara P R, Shah N S, Doshi R K and Parekh H H, *Ind J Chem* 38bB, 1999, 572
9. Krall A C, Penng J K, White B G, Kpferleg H G, Swingard E A, *Anticonvulsant drug screening Epilipria*, 19, 1978, 409-428
10. Microbiological assay of antibiotics, *Indian Pharmacopoeia, II*, 1996, 544

Source of support: Nil, Conflict of interest: None Declared